|
|
|
|
|
Nimodipine
drug data and news
Nimodipine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Nimodipine | ||
| Brand Names/Synonyms | Nimodipine; Nimodipine [Usan:Ban:Inn]; Nimodipino [Inn-Spanish]; Nimodipinum [Inn-Latin]; Nimotop; Periplum | ||
| Indication | Subarachnoid bleeding | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Nimodipine belongs to the class of pharmacological agents known as calcium channel blockers. Nimodipine is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured congenital aneurysms who are in good neurological condition post-ictus (e.g., Hunt and Hess Grades I-III). The contractile processes of smooth muscle cells are dependent upon calcium ions, which enter these cells during depolarization as slow ionic transmembrane currents. Nimodipine inhibits calcium ion transfer into these cells and thus inhibits contractions of vascular smooth muscle. In animal experiments, Nimodipine had a greater effect on cerebral arteries than on arteries elsewhere in the body perhaps because it is highly lipophilic, allowing it to cross the blood brain barrier. | ||
| Mechanism Of Action | Although the precise mechanism of action is not known, Nimodipine blocks intracellular influx of calcium that is thought to be a central to ischaemic neuronal damage. | ||
| Nimodipine News (When available) |
FDA Alerts Healthcare Professionals About Nimodipine (Nimotop) ... Feb 16, 2006 FDA Announces Nimotop (nimodipine) Boxed Warning to Notify ... Feb 16, 2006 FDA Requests Nimodipine (Nimotop) Label Change Jan 31, 2006 Alert for Healthcare Professionals Nimodipine (marketed as Nimotop ... Jan 31, 2006 Perioperative Nimodipine and Postoperative Analgesia Jan 29, 2006 Selective Intraarterial Nimodipine Treatment in an Experimental ... Jun 14, 2005 Selective Intraarterial Nimodipine Treatment in an Experimental ... Jun 14, 2005 The Treatment of Bipolar Disorder – Medications for Mania Jun 8, 2005 Index of Online Supplemental Material for Jun 6, 2005 Molecular mechanisms in successful peripheral regeneration May 27, 2005 The Treatment of Bipolar Disorder – Medications for Mania Apr 14, 2005 the AAP Division of Health Care Finance and Practice Apr 1, 2005 Practice Guidelines for Management of Migraine in Children and ... Apr 1, 2005 Brain Attack A Look at Stroke Prevention and Treatment Mar 14, 2005 Brain Attack A Look at Stroke Prevention and Treatment 14 Mar 2005 | ||
| Dosage Forms | CAPSULE | ||
| Drug_Category | Vasodilator Agents; Antihypertensive Agents; Vasodilator Agents; ATC:C08CA06 | ||
| Absorption | Not Available | ||
| Interactions |
-->Interactions for Nimodipine: It is possible that the cardiovascular action of other calcium channel blockers could be enhanced by the addition of NimotopÒ. In Europe, NimotopÒ was observed to occasionally intensify the effect of antihypertensive compounds taken concomitantly by patients suffering from hypertension; this phenomenon was not observed in North American clinical trials. A study in eight healthy volunteers has shown a 50% increase in mean peak nimodipine plasma concentrations and a 90% increase in mean area under the curve, after a one week course of cimetidine at 1,000 mg/day and nimodipine at 90 mg/day. This effect may be mediated by the known inhibition of hepatic cytochrome P- 450 by cimetidine, which could decrease first pass metabolism of nimodipine. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 2-methoxyethyl1-methylethyl2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate | ||
| Chemical Formula | C21H26N2O7 | ||
| Molecular Weight | 418.44 g/mol | ||
| Smiles String | CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC | ||
| Melting Point | Not Available | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | 3.152 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | 8-9 hours | ||
| Protein Binding [%] | 95% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Nimodipine.html http://www.rxlist.com/cgi/generic2/nimodip.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00612 | ||
| CAS Registry Number | 66085-59-4 | ||
| KEGG Compound ID | C07267 | ||
| PubChem ID | SID:187034 | ||
| PharmGKB ID | PA450633 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2155923 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |